WO2004037159A2 - Composes, compositions et methodes permettant de moduler le metabolisme des graisses - Google Patents

Composes, compositions et methodes permettant de moduler le metabolisme des graisses Download PDF

Info

Publication number
WO2004037159A2
WO2004037159A2 PCT/IL2003/000860 IL0300860W WO2004037159A2 WO 2004037159 A2 WO2004037159 A2 WO 2004037159A2 IL 0300860 W IL0300860 W IL 0300860W WO 2004037159 A2 WO2004037159 A2 WO 2004037159A2
Authority
WO
WIPO (PCT)
Prior art keywords
absent
pharmaceutical composition
cra
apobec
computer readable
Prior art date
Application number
PCT/IL2003/000860
Other languages
English (en)
Other versions
WO2004037159A3 (fr
Inventor
Georges Gaudriault
Ahmet Kilinc
Olivier Bousquet
Anne Goupil-Lamy
Itzik Harosh
Original Assignee
Obetherapy Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obetherapy Biotechnology filed Critical Obetherapy Biotechnology
Priority to AU2003274652A priority Critical patent/AU2003274652A1/en
Publication of WO2004037159A2 publication Critical patent/WO2004037159A2/fr
Publication of WO2004037159A3 publication Critical patent/WO2004037159A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des méthodes, des compositions ainsi que des méthodes d'identification de composés candidats, permettant de moduler le métabolisme des graisses et/ou d'inhiber l'activité de Apobec-1.
PCT/IL2003/000860 2002-10-23 2003-10-23 Composes, compositions et methodes permettant de moduler le metabolisme des graisses WO2004037159A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003274652A AU2003274652A1 (en) 2002-10-23 2003-10-23 Compounds, compositions and methods for modulating fat metabolism

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42031602P 2002-10-23 2002-10-23
US60/420,316 2002-10-23

Publications (2)

Publication Number Publication Date
WO2004037159A2 true WO2004037159A2 (fr) 2004-05-06
WO2004037159A3 WO2004037159A3 (fr) 2004-07-15

Family

ID=32176552

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2003/000860 WO2004037159A2 (fr) 2002-10-23 2003-10-23 Composes, compositions et methodes permettant de moduler le metabolisme des graisses

Country Status (2)

Country Link
AU (1) AU2003274652A1 (fr)
WO (1) WO2004037159A2 (fr)

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1598354A1 (fr) * 2004-05-18 2005-11-23 Vasopharm Biotech GmbH Composes contenant un groupement n-heteroaryle lie a un cycle condense et leur utilisation comme inhibiteurs du nad(p)h oxidases et de l'activation plaquettaire
WO2006066937A2 (fr) * 2004-12-23 2006-06-29 Develogen Aktiengesellschaft Nouvelle utilisation des pyrazolopyrimidines
EP1694642A2 (fr) * 2003-12-19 2006-08-30 Koronis Pharmaceuticals, Inc. Heterocycles mutagenes
WO2007041863A1 (fr) * 2005-10-14 2007-04-19 Min Zhuo Methode de traitement de la douleur neuronale et non neuronale
WO2007139497A1 (fr) * 2006-05-30 2007-12-06 Aprea Ab Dérivés levoglucosenone pour le traitement de troubles tels que cancer, maladies auto-immunes et maladies du cœur.
JP2008508215A (ja) * 2004-07-30 2008-03-21 マイコス イタリアーナ ディ コミーニ ミロ アンド チ． エッセ．ア．エッセ アミノ酸及び植物タンパク加水分解物でのジカルボン酸のｎ−アシル化誘導体ならびに化粧品及び医薬におけるそれらの使用
JP2008540652A (ja) * 2005-05-17 2008-11-20 シェーリング コーポレイション 脂質異常症の処置のための、ニコチン酸受容体アゴニストとしての複素環
WO2008147283A1 (fr) * 2007-05-25 2008-12-04 Leif Salford Utilisation de zéburaline pour le traitement de maladies autoimmunitaires ou pour un rejet immunitaire de greffes
KR100881137B1 (ko) * 2007-08-07 2009-02-02 충남대학교산학협력단 신규 돼지 페로몬 성 화합물과 그 제조방법 및 발정 유도용조성물
KR100883548B1 (ko) * 2008-10-15 2009-02-13 충남대학교산학협력단 돼지 페로몬성 우레아계 화합물과 그 제조방법 및 이를 함유하는 발정 유도용 조성물
EP2043630A2 (fr) * 2006-07-10 2009-04-08 Institute of Experimental Botany, Academy of Sciences of the Czech Republic Dérivés de purine 6,9-disubstitués et leur utilisation pour le traitement de la peau
US20090169507A1 (en) * 2003-07-25 2009-07-02 Idenix Pharmaceuticals, Inc. Purine nucleoside analogues for treating flaviviridae including hepatitis c
JP2010509397A (ja) * 2006-11-15 2010-03-25 シェーリング コーポレイション 窒素を含むヘテロ環化合物およびその使用方法
US7750015B2 (en) 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
EP2204154A1 (fr) 2008-12-30 2010-07-07 L'oreal Association de monosaccharides et d'adénosine et son utilisation en cosmétique
US7763623B2 (en) 2006-01-20 2010-07-27 Schering Corporation Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
US7850955B2 (en) * 2006-01-06 2010-12-14 Ajinomoto Co., Inc. Gelling agent
WO2011047982A2 (fr) 2009-10-22 2011-04-28 L'oreal Utilisation d'adénosine et/ou d'un de ses dérivés en tant qu'agent pour le traitement de la transpiration humaine
WO2011085000A2 (fr) * 2010-01-06 2011-07-14 The University Of North Carolina At Chapel Hill Dérivés d'acides gras et analogues de médicaments
JP2011524391A (ja) * 2008-06-17 2011-09-01 インスティチュート・パスツール・コリア 抗結核剤としてのピリドピリミジン化合物
WO2012027695A1 (fr) * 2010-08-26 2012-03-01 Northeastern University Méthodes et compositions pour la prévention ou le traitement de l'obésité
US8143289B2 (en) 2008-11-13 2012-03-27 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
EP2462133A1 (fr) * 2009-08-07 2012-06-13 Dow AgroSciences LLC Dérivés de 5-fluoro-2-oxopyrimidine-1(2h)-carboxylate
EP2462132A4 (fr) * 2009-08-07 2013-01-16 Dow Agrosciences Llc Dérivés de 5-fluoropyrimidinone
US8486953B2 (en) 2008-08-26 2013-07-16 Boehringer Ingelheim International Gmbh Thienopyrimidines for pharmaceutical compositions
WO2013137832A1 (fr) * 2012-03-16 2013-09-19 Nanyang Technological University Inhibiteurs de myostatine
US8633201B2 (en) 2006-04-07 2014-01-21 Boehringer Ingelheim International Gmbh Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions
US8648068B2 (en) 2010-02-26 2014-02-11 Boehringer Ingelheim International Gmbh Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions
US8697713B2 (en) 2006-07-10 2014-04-15 Boehringer Ingelheim International Gmbh Pyrrolopyrimidines for pharmaceutical compositions
US8716482B2 (en) 2009-09-25 2014-05-06 Merck Sharp & Dohme Corp. Substituted aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
WO2014070771A1 (fr) * 2012-10-29 2014-05-08 Rfs Pharma, Llc Nucléotides pyrimidines et leurs promédicaments monophosphates pour le traitement d'infections virales et du cancer
US8754079B2 (en) 2010-02-26 2014-06-17 Boehringer Ingelheim International Gmbh Cycloalkyl containing thienopyrimidines for pharmaceutical compositions
US8809344B2 (en) 2008-10-29 2014-08-19 Apath, Llc Compounds, compositions, and methods for control of hepatitis C viral infections
US8853193B2 (en) 2010-02-26 2014-10-07 Boehringer Ingelheim International Gmbh Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions
US9073960B2 (en) 2011-12-22 2015-07-07 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9126999B2 (en) 2012-05-31 2015-09-08 Eisai R&D Management Co., Ltd. Tetrahydropyrazolopyrimidine compounds
US9243022B2 (en) 2012-12-21 2016-01-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9422323B2 (en) 2012-05-25 2016-08-23 Janssen Sciences Ireland Uc Uracyl spirooxetane nucleosides
US9675593B2 (en) 2012-10-02 2017-06-13 Intermune, Inc. Anti-fibrotic pyridinones
US9771332B2 (en) 2015-05-05 2017-09-26 Pfizer Inc. 2-thiopyrimidinones
US9840475B2 (en) 2012-12-28 2017-12-12 Adama Makhteshim Ltd. N-(substituted)-5-fluoro-4-imino-3-methyl-2-oxo-3,4-dihydropyrimidine-1(2H)-carboxamide derivatives
US9862743B2 (en) 2013-10-11 2018-01-09 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9873673B2 (en) 2011-11-11 2018-01-23 Pfizer Inc. 2-thiopyrimidinones
US9908855B2 (en) 2012-12-28 2018-03-06 Adama Makhteshim Ltd. N-(substituted)-5-fluoro-4-imino-3-methyl-2-oxo-3,4-dihydropyrimidine-1(2H)-carboxylate derivatives
US10010536B2 (en) 2005-05-10 2018-07-03 Intermune, Inc. Method of modulating stress-activated protein kinase system
US10059703B2 (en) 2012-12-31 2018-08-28 Adama Makhteshim Ltd. 3-alkyl-5-fluoro-4-substituted-imino-3,4-dihydropyrimidin-2(1H)-one derivatives as fungicides
USRE47142E1 (en) 2008-06-03 2018-11-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
WO2019052359A1 (fr) * 2017-09-14 2019-03-21 辽宁利锋科技开发有限公司 Effet antitumoral et utilisation d'analogue de ribavirine dihétérocyclique
US10485815B2 (en) 2012-03-21 2019-11-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US10618899B2 (en) 2015-02-18 2020-04-14 Buck Institute For Research On Aging Substituted [1,2,3]triazolo[4,5-d]pyrimidines that lower stress-induced p-tau
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN115501234A (zh) * 2021-08-02 2022-12-23 中山大学·深圳 化合物在制备防治脱髓鞘疾病药物的用途
WO2023044104A1 (fr) * 2021-09-17 2023-03-23 Emory University Phosphoramidates pour le traitement du virus de l'hépatite b
US11697666B2 (en) 2021-04-16 2023-07-11 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
US11767337B2 (en) 2020-02-18 2023-09-26 Gilead Sciences, Inc. Antiviral compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NOVOTNY L. ET AL: 'Polarographic properties and potential carcinogenicity of some natural nucleosides and their synthetic analogues' BIOELECTROCHEMISTRY AND BIOENERGETICS vol. 48, 1999, pages 129 - 134, XP002979005 *
SAMILJENKO S.P. ET AL: 'Structural peculiarities of 6-azacytosine and its derivatives imply intramolecular H-bonds' J. OF MOLECULAR STRUCTURE vol. 484, 1999, pages 31 - 38, XP002979006 *

Cited By (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090169507A1 (en) * 2003-07-25 2009-07-02 Idenix Pharmaceuticals, Inc. Purine nucleoside analogues for treating flaviviridae including hepatitis c
US8742101B2 (en) * 2003-07-25 2014-06-03 Idenix Pharmaceuticals, Inc. Purine nucleoside analogues for treating flaviviridae including hepatitis C
EP1694642A4 (fr) * 2003-12-19 2010-10-06 Koronis Pharmaceuticals Inc Heterocycles mutagenes
EP1694642A2 (fr) * 2003-12-19 2006-08-30 Koronis Pharmaceuticals, Inc. Heterocycles mutagenes
JP2007538029A (ja) * 2004-05-18 2007-12-27 ヴァソファルム・ゲーエムベーハー 縮合環部分へ連結したｎ−ヘテロアリール部分を含有する、ｎａｄ（ｐ）ｈオキシダーゼ及び血小板活性化の阻害のための化合物
CN1989140B (zh) * 2004-05-18 2012-01-11 瓦索珐姆有限公司 用于抑制nad(p)h氧化酶和血小板活化的含有与稠合环部分连接的n-杂芳基部分的化合物
KR101300412B1 (ko) 2004-05-18 2013-08-26 바조팜 게엠베하 Ｎａｄ(ｐ)ｈ 산화효소와 혈소판 활성화 억제를 위한 융합고리 부분과 결합된 ｎ-헤테로아릴 부분을 포함하는 화합물
EP1598354A1 (fr) * 2004-05-18 2005-11-23 Vasopharm Biotech GmbH Composes contenant un groupement n-heteroaryle lie a un cycle condense et leur utilisation comme inhibiteurs du nad(p)h oxidases et de l'activation plaquettaire
US8236809B2 (en) 2004-05-18 2012-08-07 Vasopharm Gmbh Substituted 1,2,3-triazolopyrimidines for the inhibition of NAD(P)H oxidases and platelet activation
WO2005111041A1 (fr) * 2004-05-18 2005-11-24 Vasopharm Biotech Gmbh Composes comprenant une fraction n-heteroaryle liee a des fractions de noyau fusionnees et destines a l'inhibition des nad(p)h oxydases et de l'activation de plaquettes
JP2008508215A (ja) * 2004-07-30 2008-03-21 マイコス イタリアーナ ディ コミーニ ミロ アンド チ． エッセ．ア．エッセ アミノ酸及び植物タンパク加水分解物でのジカルボン酸のｎ−アシル化誘導体ならびに化粧品及び医薬におけるそれらの使用
EP1746099A1 (fr) * 2004-12-23 2007-01-24 DeveloGen Aktiengesellschaft Inhibiteurs de Mnk1 ou Mnk2
WO2006066937A3 (fr) * 2004-12-23 2006-10-19 Develogen Ag Nouvelle utilisation des pyrazolopyrimidines
US8071607B2 (en) 2004-12-23 2011-12-06 Boehringer Ingelheim International Gmbh Mnk1 or Mnk2 inhibitors
WO2006066937A2 (fr) * 2004-12-23 2006-06-29 Develogen Aktiengesellschaft Nouvelle utilisation des pyrazolopyrimidines
US10010536B2 (en) 2005-05-10 2018-07-03 Intermune, Inc. Method of modulating stress-activated protein kinase system
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US7723342B2 (en) 2005-05-17 2010-05-25 Schering Corporation Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
US7750015B2 (en) 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
JP2008540652A (ja) * 2005-05-17 2008-11-20 シェーリング コーポレイション 脂質異常症の処置のための、ニコチン酸受容体アゴニストとしての複素環
AU2006247695B2 (en) * 2005-05-17 2012-08-09 Merck Sharp & Dohme Corp. Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
US8124599B2 (en) 2005-10-14 2012-02-28 Min Zhuo Method for treating neuronal and non-neuronal pain
CN1947717B (zh) * 2005-10-14 2012-09-26 卓敏 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用
WO2007041863A1 (fr) * 2005-10-14 2007-04-19 Min Zhuo Methode de traitement de la douleur neuronale et non neuronale
US7850955B2 (en) * 2006-01-06 2010-12-14 Ajinomoto Co., Inc. Gelling agent
US7763623B2 (en) 2006-01-20 2010-07-27 Schering Corporation Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
US8633201B2 (en) 2006-04-07 2014-01-21 Boehringer Ingelheim International Gmbh Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions
WO2007139497A1 (fr) * 2006-05-30 2007-12-06 Aprea Ab Dérivés levoglucosenone pour le traitement de troubles tels que cancer, maladies auto-immunes et maladies du cœur.
EP2043630A2 (fr) * 2006-07-10 2009-04-08 Institute of Experimental Botany, Academy of Sciences of the Czech Republic Dérivés de purine 6,9-disubstitués et leur utilisation pour le traitement de la peau
US8697713B2 (en) 2006-07-10 2014-04-15 Boehringer Ingelheim International Gmbh Pyrrolopyrimidines for pharmaceutical compositions
EP2043630B1 (fr) * 2006-07-10 2016-09-07 Institute of Experimental Botany, Academy of Sciences of the Czech Republic Dérivés de purine 6,9-disubstitués à usage cosmétique
JP2010509397A (ja) * 2006-11-15 2010-03-25 シェーリング コーポレイション 窒素を含むヘテロ環化合物およびその使用方法
WO2008147283A1 (fr) * 2007-05-25 2008-12-04 Leif Salford Utilisation de zéburaline pour le traitement de maladies autoimmunitaires ou pour un rejet immunitaire de greffes
KR100881137B1 (ko) * 2007-08-07 2009-02-02 충남대학교산학협력단 신규 돼지 페로몬 성 화합물과 그 제조방법 및 발정 유도용조성물
USRE47142E1 (en) 2008-06-03 2018-11-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
JP2011524391A (ja) * 2008-06-17 2011-09-01 インスティチュート・パスツール・コリア 抗結核剤としてのピリドピリミジン化合物
US8785452B2 (en) 2008-06-17 2014-07-22 Institut National De La Sante Et De La Recherche Medicale Anti-infective compounds
US8486953B2 (en) 2008-08-26 2013-07-16 Boehringer Ingelheim International Gmbh Thienopyrimidines for pharmaceutical compositions
KR100883548B1 (ko) * 2008-10-15 2009-02-13 충남대학교산학협력단 돼지 페로몬성 우레아계 화합물과 그 제조방법 및 이를 함유하는 발정 유도용 조성물
US8809344B2 (en) 2008-10-29 2014-08-19 Apath, Llc Compounds, compositions, and methods for control of hepatitis C viral infections
US8415297B2 (en) 2008-11-13 2013-04-09 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US8772328B2 (en) 2008-11-13 2014-07-08 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US8951965B2 (en) 2008-11-13 2015-02-10 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US9403790B2 (en) 2008-11-13 2016-08-02 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US8592371B2 (en) 2008-11-13 2013-11-26 Merck Sharpe & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US9278976B2 (en) 2008-11-13 2016-03-08 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
US9138426B2 (en) 2008-11-13 2015-09-22 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
US8143289B2 (en) 2008-11-13 2012-03-27 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
EP2204154A1 (fr) 2008-12-30 2010-07-07 L'oreal Association de monosaccharides et d'adénosine et son utilisation en cosmétique
KR101779626B1 (ko) * 2009-08-07 2017-09-18 아다마 마켓심 리미티드 5-플루오로피리미디논 유도체
AU2010279408B2 (en) * 2009-08-07 2015-09-10 Adama Makhteshim Ltd. 5-fluoro-2-oxopyrimidine- 1(2H)-carboxylate derivatives
JP2013501724A (ja) * 2009-08-07 2013-01-17 ダウ アグロサイエンシィズ エルエルシー ５−フルオロピリミジノン誘導体
EP2462133A4 (fr) * 2009-08-07 2013-01-16 Dow Agrosciences Llc Dérivés de 5-fluoro-2-oxopyrimidine-1(2h)-carboxylate
EP2462132A4 (fr) * 2009-08-07 2013-01-16 Dow Agrosciences Llc Dérivés de 5-fluoropyrimidinone
AU2010279404B2 (en) * 2009-08-07 2016-05-12 Adama Makhteshim Ltd. 5-fluoropyrimidinone derivatives
EP2462133A1 (fr) * 2009-08-07 2012-06-13 Dow AgroSciences LLC Dérivés de 5-fluoro-2-oxopyrimidine-1(2h)-carboxylate
US8716482B2 (en) 2009-09-25 2014-05-06 Merck Sharp & Dohme Corp. Substituted aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
WO2011047982A2 (fr) 2009-10-22 2011-04-28 L'oreal Utilisation d'adénosine et/ou d'un de ses dérivés en tant qu'agent pour le traitement de la transpiration humaine
WO2011085000A3 (fr) * 2010-01-06 2011-09-09 The University Of North Carolina At Chapel Hill Dérivés d'acides gras et analogues de médicaments
WO2011085000A2 (fr) * 2010-01-06 2011-07-14 The University Of North Carolina At Chapel Hill Dérivés d'acides gras et analogues de médicaments
US8853193B2 (en) 2010-02-26 2014-10-07 Boehringer Ingelheim International Gmbh Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions
US8648068B2 (en) 2010-02-26 2014-02-11 Boehringer Ingelheim International Gmbh Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions
US8754079B2 (en) 2010-02-26 2014-06-17 Boehringer Ingelheim International Gmbh Cycloalkyl containing thienopyrimidines for pharmaceutical compositions
WO2012027695A1 (fr) * 2010-08-26 2012-03-01 Northeastern University Méthodes et compositions pour la prévention ou le traitement de l'obésité
US9873673B2 (en) 2011-11-11 2018-01-23 Pfizer Inc. 2-thiopyrimidinones
US10464965B2 (en) 2011-12-22 2019-11-05 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9073960B2 (en) 2011-12-22 2015-07-07 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US11021509B2 (en) 2011-12-22 2021-06-01 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2013137832A1 (fr) * 2012-03-16 2013-09-19 Nanyang Technological University Inhibiteurs de myostatine
US10485815B2 (en) 2012-03-21 2019-11-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US10774106B2 (en) 2012-05-25 2020-09-15 Janssen Sciences Ireland Unlimited Company Uracyl spirooxetane nucleosides
US10040814B2 (en) 2012-05-25 2018-08-07 Janssen Sciences Ireland Uc Uracyl spirooxetane nucleosides
US10544184B2 (en) 2012-05-25 2020-01-28 Janssen Sciences Ireland Unlimited Company Uracyl spirooxetane nucleosides
US9845336B2 (en) 2012-05-25 2017-12-19 Janssen Sciences Ireland Uc Uracyl spirooxetane nucleosides
US10301347B2 (en) 2012-05-25 2019-05-28 Janssen Sciences Ireland Unlimited Company Uracyl spirooxetane nucleosides
US9422323B2 (en) 2012-05-25 2016-08-23 Janssen Sciences Ireland Uc Uracyl spirooxetane nucleosides
US10640500B2 (en) 2012-05-31 2020-05-05 Eisai R&D Management Co., Ltd. Tetrahydropyrazolopyrimidine compounds
US9126999B2 (en) 2012-05-31 2015-09-08 Eisai R&D Management Co., Ltd. Tetrahydropyrazolopyrimidine compounds
US9850242B2 (en) 2012-05-31 2017-12-26 Eisai R&D Management Co., Ltd Tetrahydropyrazolopyrimidine compounds
US11130758B2 (en) 2012-05-31 2021-09-28 Eisai R&D Management Co., Ltd. Tetrahydropyrazolopyrimidine compounds
US9446046B2 (en) 2012-05-31 2016-09-20 Eisai R&D Management Co., Ltd. Tetrahydropyrazolopyrimidine compounds
US9675593B2 (en) 2012-10-02 2017-06-13 Intermune, Inc. Anti-fibrotic pyridinones
US10898474B2 (en) 2012-10-02 2021-01-26 Intermune, Inc. Anti-fibrotic pyridinones
US10376497B2 (en) 2012-10-02 2019-08-13 Intermune, Inc. Anti-fibrotic pyridinones
WO2014070771A1 (fr) * 2012-10-29 2014-05-08 Rfs Pharma, Llc Nucléotides pyrimidines et leurs promédicaments monophosphates pour le traitement d'infections virales et du cancer
CN104884462A (zh) * 2012-10-29 2015-09-02 共晶制药股份有限公司 用于治疗病毒感染和癌症的嘧啶核苷及其单磷酸酯前药
JP2015535261A (ja) * 2012-10-29 2015-12-10 コクリスタル ファーマ，インコーポレイテッド ウイルス感染及び癌の治療のためのピリミジンヌクレオチド及びその一リン酸プロドラッグ
US9809616B2 (en) 2012-10-29 2017-11-07 Emory University Pyrimidine nucleosides and their monophosphate prodrugs for the treatment of viral infections and cancer
US10112966B2 (en) 2012-12-21 2018-10-30 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9249174B2 (en) 2012-12-21 2016-02-02 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US10793591B2 (en) 2012-12-21 2020-10-06 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9243022B2 (en) 2012-12-21 2016-01-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US10487104B2 (en) 2012-12-21 2019-11-26 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US10144755B2 (en) 2012-12-21 2018-12-04 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US10683320B2 (en) 2012-12-21 2020-06-16 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US11485753B2 (en) 2012-12-21 2022-11-01 Janssen Pharmaceutica Nv Substituted nucleosides, nucleotides and analogs thereof
US9840475B2 (en) 2012-12-28 2017-12-12 Adama Makhteshim Ltd. N-(substituted)-5-fluoro-4-imino-3-methyl-2-oxo-3,4-dihydropyrimidine-1(2H)-carboxamide derivatives
US9908855B2 (en) 2012-12-28 2018-03-06 Adama Makhteshim Ltd. N-(substituted)-5-fluoro-4-imino-3-methyl-2-oxo-3,4-dihydropyrimidine-1(2H)-carboxylate derivatives
US10059703B2 (en) 2012-12-31 2018-08-28 Adama Makhteshim Ltd. 3-alkyl-5-fluoro-4-substituted-imino-3,4-dihydropyrimidin-2(1H)-one derivatives as fungicides
US9862743B2 (en) 2013-10-11 2018-01-09 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US10370401B2 (en) 2013-10-11 2019-08-06 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US10544161B2 (en) 2014-04-02 2020-01-28 Intermune, Inc. Anti-fibrotic pyridinones
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
US10618899B2 (en) 2015-02-18 2020-04-14 Buck Institute For Research On Aging Substituted [1,2,3]triazolo[4,5-d]pyrimidines that lower stress-induced p-tau
US10844071B2 (en) 2015-02-18 2020-11-24 Buck Institute For Research On Aging Substituted [1,2,3]triazolo[4,5-d]pyrimidines that lower stress-induced p-tau
US9771332B2 (en) 2015-05-05 2017-09-26 Pfizer Inc. 2-thiopyrimidinones
WO2019052359A1 (fr) * 2017-09-14 2019-03-21 辽宁利锋科技开发有限公司 Effet antitumoral et utilisation d'analogue de ribavirine dihétérocyclique
US11767337B2 (en) 2020-02-18 2023-09-26 Gilead Sciences, Inc. Antiviral compounds
US11697666B2 (en) 2021-04-16 2023-07-11 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
CN115501234A (zh) * 2021-08-02 2022-12-23 中山大学·深圳 化合物在制备防治脱髓鞘疾病药物的用途
CN115501234B (zh) * 2021-08-02 2023-08-08 中山大学·深圳 化合物在制备防治脱髓鞘疾病药物的用途
WO2023044104A1 (fr) * 2021-09-17 2023-03-23 Emory University Phosphoramidates pour le traitement du virus de l'hépatite b

Also Published As

Publication number Publication date
AU2003274652A1 (en) 2004-05-13
WO2004037159A3 (fr) 2004-07-15
AU2003274652A8 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
WO2004037159A2 (fr) Composes, compositions et methodes permettant de moduler le metabolisme des graisses
Bauman et al. Detecting allosteric sites of HIV-1 reverse transcriptase by X-ray crystallographic fragment screening
Fischer et al. Cyclin-dependent kinase inhibitors
Wu et al. Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop
Sloane et al. Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237
Knight et al. A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling
Schulze-Gahmen et al. High-resolution crystal structures of human cyclin-dependent kinase 2 with and without ATP: bound waters and natural ligand as guides for inhibitor design
De Baere et al. Purification of porcine brain protein phosphatase 2A leucine carboxyl methyltransferase and cloning of the human homologue
Bidon-Chanal et al. Evidence for a new binding mode to GSK-3: Allosteric regulation by the marine compound palinurin
Himmel et al. HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel site
Getlik et al. Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc
Battistutta et al. Inspecting the structure-activity relationship of protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole
Qiao et al. Small molecule modulators targeting protein kinase CK1 and CK2
Rogers et al. Discovery of protein phosphatase 2C inhibitors by virtual screening
Mejdrová et al. Rational design of novel highly potent and selective phosphatidylinositol 4-kinase IIIβ (PI4KB) inhibitors as broad-spectrum antiviral agents and tools for chemical biology
Dreyer et al. Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717
Drew et al. Discovery of potent and selective PI3Kγ inhibitors
Tesch et al. Structure-based design of selective salt-inducible kinase inhibitors
Zhu et al. Targeting phosphatidylinositol 3‐kinase gamma (PI3Kγ): Discovery and development of its selective inhibitors
Mehellou et al. Structural insights into the activation of MST3 by MO25
Zheng et al. Definition of the binding mode of a new class of phosphoinositide 3-kinase α-selective inhibitors using in vitro mutagenesis of non-conserved amino acids and kinetic analysis
Ali et al. A comparative study of AutoDock and PMF scoring performances, and SAR of 2-substituted pyrazolotriazolopyrimidines and 4-substituted pyrazolopyrimidines as potent xanthine oxidase inhibitors
Tan et al. An updated patent review of autotaxin inhibitors (2017–present)
D’Antonio et al. Structure-based approach to the identification of a novel group of selective glucosamine analogue inhibitors of Trypanosoma cruzi glucokinase
Gardino et al. The NMR solution structure of BeF3−-activated Spo0F reveals the conformational switch in a phosphorelay system

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP